Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Prostatic Neoplasms 147Breast Neoplasms 108Lung Neoplasms 93Carcinoma, Non-Small-Cell Lung 78Neoplasm Metastasis 68Glioblastoma 68Brain Neoplasms 65Glioma 59Pancreatic Neoplasms 46Carcinoma, Renal Cell 43Multiple Myeloma 41Squamous Cell Carcinoma of Head and Neck 39Colorectal Neoplasms 39Lymphoma, Large B-Cell, Diffuse 37Neoplasms 34Melanoma 33Lymphoma 32Carcinoma, Hepatocellular 32Urinary Bladder Neoplasms 31Ovarian Neoplasms 29Astrocytoma 28Sarcoma 25Oropharyngeal Neoplasms 24Lymphoma, Follicular 23Central Nervous System Neoplasms 23Rectal Neoplasms 22Uterine Cervical Neoplasms 21Triple Negative Breast Neoplasms 21Mouth Neoplasms 21Lymphoma, Non-Hodgkin 21

Interventions

Doxorubicin 9Imatinib Mesylate 6pazopanib 4Ifosfamide 4Radiotherapy 3Gemcitabine 3Docetaxel 3pembrolizumab 2Radiation 2Neoadjuvant Therapy 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2selinexor 1saracatinib 1sapanisertib 1ribociclib 1peposertib 1liposomal doxorubicin 1indolepropanol phosphate 1envafolimab 1cixutumumab 1brigimadlin 1avelumab 1X-Rays 1Watchful Waiting 1TTI-621 1Sunitinib 1Specimen Handling 1Razoxane 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dermatofibrosarcoma × Magnetic Resonance Spectroscopy × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡